Search results for "Nicotinic agonist"

showing 8 items of 118 documents

Smokeless tobacco, sport and the heart

2014

SummarySmokeless tobacco (snuff) is a finely ground or shredded tobacco that is sniffed through the nose or placed between the cheek and gum. Chewing tobacco is used by putting a wad of tobacco inside the cheek. Smokeless tobacco is widely used by young athletes to enhance performance because nicotine improves some aspects of physiology. However, smokeless tobacco has harmful health effects, including cardiovascular disorders, linked to nicotine physiological effects, mainly through catecholamine release. Nicotine decreases heart rate variability and the ventricular fibrillation threshold, and promotes the occurrence of various arrhythmias; it also impairs endothelial-dependent vasodilation…

medicine.medical_specialtyNicotineTime FactorsTobacco SmokelessEffets cardiovasculairesTabac non fuméPerformance-Enhancing SubstancesAthletic PerformanceCardiovascular SystemRisk AssessmentNicotineRisk FactorsInternal medicineHeart rateDopingMedicineHeart rate variabilityHumansSnuffNicotinic AgonistsSportDoping in Sportsbusiness.industryHemodynamicsCardiovascular effectsGeneral MedicineSurgerystomatognathic diseasesChewing tobaccoBlood pressureDopageSmokeless tobaccoAthletesSmokeless tobaccoCardiologyMasticationbusinessCardiology and Cardiovascular MedicineAnaerobic exercisemedicine.drugSportsArchives of Cardiovascular Diseases
researchProduct

Allosteric sensitization of nicotinic receptors by galantamine, a new treatment strategy for Alzheimer’s disease

2001

Cholinesterase inhibitors are the only approved drug treatment for patients with mild to moderately severe Alzheimer's disease. Interestingly, the clinical potency of these drugs does not correlate well with their activity as cholinesterase inhibitors, nor is their action as short lived as would be expected from purely symptomatic treatment. A few cholinesterase inhibitors, including galantamine, produce beneficial effects even after drug treatment has been terminated. These effects assume modes of action other than mere esterase inhibition and are capable of inducing systemic changes. We have recently discovered a mechanism that could account, at least in part, for the above-mentioned unex…

medicine.medical_specialtyPatch-Clamp TechniquesReceptors NicotinicPharmacologyCell LineMiceAllosteric RegulationAlzheimer DiseaseInternal medicinemedicineGalantamineAnimalsHumansNootropic AgentsBiological PsychiatryCholinesteraseAcetylcholine receptorNeuronsbiologyGalantamineChemistryNicotinic acetylcholine receptorNicotinic agonistEndocrinologyMechanism of actionTacrinebiology.proteinCholinesterase Inhibitorsmedicine.symptomAllosteric SiteAcetylcholinemedicine.drugBiological Psychiatry
researchProduct

Evidence for a respiration-modulated cholinergic action on the activity of medullary respiration-related neurons in the rabbit. An iontophoretic stud…

1989

Effects of the iontophoretically administered cholinergic agonists acetylcholine, bethanechol and DMPP on the activity of medullary respiration-related neurons were examined in urethane-anaesthetized rabbits. Inhibitory effects prevailed over excitatory effects. Analysis of cholinergic effects by cycle-triggered averaging revealed three major types of neuronal responses: (i) constant alterations of spike-density throughout the whole period of activity ("constant effects"), (ii) effects increasing during the progression of the burst of discharge or effects restricted to a particular fraction of the burst ("phasic effects") and (iii) effects which were characterized by an excitation during on…

medicine.medical_specialtyPhysiologyClinical BiochemistryRespiratory SystemAction PotentialsBethanecholHexamethonium CompoundsInhibitory postsynaptic potentialHexamethoniumchemistry.chemical_compoundBethanechol CompoundsPhysiology (medical)Internal medicineMuscarinic acetylcholine receptormedicineAnimalsNeurotransmitterNeuronsRespirationBethanecholIontophoresisReceptors MuscarinicAcetylcholineElectrophysiologyNicotinic agonistmedicine.anatomical_structureEndocrinologychemistryCholinergicNeuronRabbitsDimethylphenylpiperazinium IodideAcetylcholinemedicine.drugPflugers Archiv : European journal of physiology
researchProduct

Release of acetylcholine from murine embryonic stem cells: Effect of nicotinic and muscarinic receptors and blockade of organic cation transporter

2012

The non-neuronal cholinergic system is widely expressed in nature. The present experiments were performed to characterize the non-neuronal cholinergic system in murine embryonic stem cells (CGR8 cell line).CGR8 cells were cultured in gelatinized flasks with Glasgow's buffered minimal essential medium (Gibco, Germany). Acetylcholine was measured by HPLC combined with bioreactor and electrochemical detection.CGR8 cells contained 1.08±0.12 pmol acetylcholine/10(6) cells (n=7) which was reduced to 0.50±0.06 pmol/10(6) cells (n=6; p0.05) in the presence (4h) of 30μM bromoacetylcholine to block choline acetyltransferase. A time-dependent release of acetylcholine into the incubation medium was dem…

medicine.medical_specialtyPhysostigmineMuscarinic AntagonistsNicotinic AntagonistsMuscarinic AgonistsReceptors NicotinicGeneral Biochemistry Genetics and Molecular BiologyCell LineMicechemistry.chemical_compoundInternal medicineMuscarinic acetylcholine receptormedicineMuscarinic acetylcholine receptor M4AnimalsCholinesterasesGeneral Pharmacology Toxicology and PharmaceuticsCation Transport ProteinsEmbryonic Stem CellsOrganic cation transport proteinsMuscarineQuininebiologyOxotremorineMuscarinic acetylcholine receptor M3Muscarinic acetylcholine receptor M2General MedicineReceptors MuscarinicAcetylcholineCell biologyEndocrinologyNicotinic agonistchemistrybiology.proteinCholinesterase InhibitorsAcetylcholinemedicine.drugLife Sciences
researchProduct

The non-neuronal cholinergic system in humans: expression, function and pathophysiology.

2003

Acetylcholine, a prime example of a neurotransmitter, has been detected in bacteria, algae, protozoa, and primitive plants, indicating an extremely early appearance in the evolutionary process (about 3 billion years). In humans, acetylcholine and/or the synthesizing enzyme, choline acetyltransferase (ChAT), have been found in epithelial cells (airways, alimentary tract, urogenital tract, epidermis), mesothelial (pleura, pericardium), endothelial, muscle and immune cells (mononuclear cells, granulocytes, alveolar macrophages, mast cells). The widespread expression of non-neuronal acetylcholine is accompanied by the ubiquitous presence of cholinesterase and receptors (nicotinic, muscarinic). …

medicine.medical_specialtyPlacentaBiologyGeneral Biochemistry Genetics and Molecular BiologyCholine O-AcetyltransferasePregnancyInternal medicineMuscarinic acetylcholine receptorMuscarinic acetylcholine receptor M5medicineMuscarinic acetylcholine receptor M4AnimalsHumansReceptors CholinergicGeneral Pharmacology Toxicology and PharmaceuticsInflammationMuscarinic acetylcholine receptor M3Muscarinic acetylcholine receptor M2General MedicineAcetylcholineCell biologyEndocrinologyNicotinic agonistCholinergicFemaleAcetylcholinemedicine.drugSubcellular FractionsLife sciences
researchProduct

The nicotinic acetylcholine receptor agonist (±)-epibatidine increases FGF-2 mRNA and protein levels in the rat brain

2000

Abstract In a previous work, we showed that acute intermittent nicotine treatment up-regulates the level of fibroblast growth factor-2 (FGF-2) mRNA in brain regions of tel- and mesencephalon of rats suggesting that neuroprotective effect of (−)nicotine may, at least in part, involve an activation of the neuronal FGF-2 signalling. The present experiments were designed to extend the study on the nicotinic receptor mediated up-regulation of FGF-2 mRNA levels to the use of the potent nicotinic acetylcholine receptor (nAChR) agonist (±)-epibatidine. The (±)-epibatidine treatment led to a strong and long lasting up-regulation of FGF-2 mRNA expression in the cerebral cortex, in the hippocampal for…

medicine.medical_specialtyTime FactorsNicotinic acetylcoline receptor agonistPyridinesBlotting WesternNerve Tissue ProteinsNicotinic AntagonistsFibroblast growth factor-2MecamylamineBiologyHippocampusRats Sprague-DawleyNicotineCellular and Molecular NeuroscienceInternal medicineMecamylaminemedicineGlial cell line-derived neurotrophic factorAnimalsGlial Cell Line-Derived Neurotrophic FactorNerve Growth FactorsNicotinic AgonistsRNA MessengerMolecular BiologyIn Situ HybridizationEpibatidineCerebral CortexBrain-derived neurotrophic factorDose-Response Relationship DrugBrain-Derived Neurotrophic FactorBrainBridged Bicyclo Compounds HeterocyclicCorpus StriatumRatsSpecific Pathogen-Free OrganismsNicotinic acetylcholine receptorEndocrinologyNicotinic agonistGene Expression RegulationEpibatidinebiology.proteinFibroblast Growth Factor 2Alpha-4 beta-2 nicotinic receptorFibroblast growth factor receptor-1medicine.drugMolecular Brain Research
researchProduct

Nicotinic receptor agonists as neuroprotective/neurotrophic drugs. Progress in molecular mechanisms

2007

In the present work we reviewed recent advances concerning neuroprotective/neurotrophic effects of acute or chronic nicotine exposure, and the signalling pathways mediating these effects, including mechanisms implicated in nicotine addiction and nAChR desensitization. Experimental and clinical data largely indicate long-lasting effects of nicotine and nicotinic agonists that imply a neuroprotective/neurotrophic role of nAChR activation, involving mainly alpha 7 and alpha 4 beta 2 nAChR subtypes, as evidenced using selective nAChR agonists. Compounds interacting with neuronal nAChRs have the potential to be neuroprotective and treatment with nAChR agonists elicits long-lasting neurotrophic e…

neuroplasticitydesensitizationFGF-2nAChRReceptors NicotinicBiologyPharmacologySettore BIO/09 - FisiologiaNeuroprotectionNicotineNeurotrophic factorsmedicineAnimalsHumansnicotinic agonistNerve Growth FactorsNicotinic Agonistsneurotrophic factorBiological PsychiatryNeuronal PlasticitynAChR; nicotinic agonists; neurotrophic factors; FGF-2; neuroprotection; neurotrophism; addiction; desensitization; neuroplasticityBrainNeurodegenerative DiseasesTobacco Use DisorderPsychiatry and Mental healthNeuroprotective AgentsNerve growth factorNicotinic agonistNeurologySynaptic plasticityneurotrophismbiology.proteinneuroprotectionaddictionNeurology (clinical)Signal transductionNeuroscienceSignal Transductionmedicine.drugNeurotrophinJournal of Neural Transmission
researchProduct

α-Conotoxins EpI and AuIB switch subtype selectivity and activity in native versus recombinant nicotinic acetylcholine receptors

2003

The Xenopus laevis oocyte expression system was used to determine the activities of alpha-conotoxins EpI and the ribbon isomer of AuIB, on defined nicotinic acetylcholine receptors (nAChRs). In contrast to previous findings on intracardiac ganglion neurones, alpha-EpI showed no significant activity on oocyte-expressed alpha3beta4 and alpha3beta2 nAChRs but blocked the alpha7 nAChR with an IC50 value of 30 nM. A similar IC50 value (103 nM) was obtained on the alpha7/5HT3 chimeric receptor stably expressed in mammalian cells. Ribbon AuIB maintained its selectivity on oocyte-expressed alpha3beta4 receptors but unlike in native cells, where it was 10-fold more potent than native alpha-AuIB, had…

α7 nicotinic acetylcholine receptorα-Conotoxin AuIBRecombinant Fusion ProteinsBiophysicsXenopusNicotinic AntagonistsReceptors NicotinicPharmacologyTransfectionBiochemistrycomplex mixturesSubstrate SpecificityInhibitory Concentration 50Xenopus laevisStructural BiologyGeneticsmedicineAnimalsConotoxinNicotinic AntagonistReceptorMolecular BiologyAcetylcholine receptorbiologyα-Conotoxin EpICell Biologybiology.organism_classificationRatsCell biologyProtein SubunitsNicotinic acetylcholine receptorNicotinic agonistnervous systemIntracardiac gangliaOocytessense organsReceptors Serotonin 5-HT3ConotoxinsAcetylcholineXenopus laevis oocytemedicine.drugFEBS Letters
researchProduct